Seok Woo Moon
The issue of the genetics in brain imaging phenotypes serves as a crucial link between two distinct scientific fields: neuroimaging genetics (NG). The articles included here provide solid proof that this NG link has considerable synergy. There is a suitable collection of articles that offer a wide range of viewpoints on how genetic variations affect brain structure and function. They serve as illustrations of several study approaches used in contemporary genetics and neuroscience. Genome-wide association studies and candidate-gene association are two examples of genetic techniques...
November 10, 2023: Current Alzheimer Research
Tongtong Li, Chong Chen, Jing Yuan, Keming Zhang, Meilin Zhang, Huichao Zhao, Xiaomin Wu, Liping Zhu, Guowei Huang, Fei Ma
BACKGROUND: Along with the problem of population aging, the prevalence of dementia is gradually increasing. Associations between vitamin D deficiency (VDD) and cognitive functions remain unclear. OBJECTIVE: We aimed to determine the relationship between VDD and changes in cognitive performance in community-dwelling older adults. METHODS: In this longitudinal cohort study, participants aged ≥65 years were enrolled in March, 2016. The serum level of 25-hydroxy-vitamin D was analyzed by liquid-chromatography-tandem-- mass-spectrometry at baseline...
November 10, 2023: Current Alzheimer Research
Daniela Merlo, Cristiana Mollinari
No abstract text is available yet for this article.
October 25, 2023: Current Alzheimer Research
Mingjuan Qiu, Di Zhou, Haiyan Zhu, Yongjia Shao, Yan Li, Yibin Wang, Genlin Zong, Qian Xi
OBJECTIVES: Cerebral blood flow (CBF) is an important index for measuring brain function. Studies have shown that regional CBF changes inconsistently in mild cognitive impairment (MCI). Arterial spin labeling (ASL) is widely used in the study of CBF in patients with MCI. However, alterations in CBF connectivity in these patients remain poorly understood. METHODS: In this study, 3D pseudo-continuous arterial spin labeling (3D-pCASL) technology was used to investigate the changes in regional CBF and CBF connectivity between 32 MCI patients and 32 healthy controls...
October 25, 2023: Current Alzheimer Research
Samuel L Warren, Eid Abo Hamza, Richard Tindle, Edwina Reid, Paige Whitfield, Adam Doumit, Ahmed A Moustafa
The Alzheimer's disease (AD) continuum is a unique spectrum of cognitive impairment that typically involves the stages of subjective memory complaints (SMC), mild cognitive impairment (MCI), and AD dementia. Neuropsychiatric symptoms (NPS), such as apathy, anxiety, stress, and depression, are highly common throughout the AD continuum. However, there is a dearth of research on how these NPS vary across the AD continuum, especially SMC. There is also disagreement on the effects of specific NPS on each stage of the AD continuum due to their collinearity with other NPS, cognitive decline, and environmental factors (e...
October 23, 2023: Current Alzheimer Research
Debjani Roy, Shymodip Kundu, Swayambhik Mukherjee
BACKGROUND: Alzheimer's disease is the most common neurodegenerative disorder. Recent development in sciences has also identified the pivotal role of microRNAs (miRNAs) in AD pathogenesis. OBJECTIVES: We proposed a novel method to identify AD pathway-specific statistically significant miRNAs from the targets of known AD drugs. Moreover, microRNA scaffolds and corresponding drug scaffolds of different pathways were also discovered. MATERIAL AND METHODS: A Wilcoxon signed-rank test was performed to identify pathway-specific significant miRNAs...
October 20, 2023: Current Alzheimer Research
Bin Zhou, Qianhua Zhao, Shinsuke Kojima, Ding Ding, Satoshi Higashide, Masanori Fukushima, Zhen Hong
INTRODUCTION: The purpose of this study is to identify the risk factors and risk classification associated with the conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia to facilitate early intervention and the design of clinical trials for AD. METHODS: The study comprised a prospective cohort study of 400 subjects with MCI who had annual follow-ups for 3 years. RESULTS: During an average follow-up period of 3...
September 14, 2023: Current Alzheimer Research
Xi-Chen Zhu, Meng-Zhuo Zhu, Jing Lu, Qing-Yu Yao, Jia-Wei Hu, Wen-Jun Long, Sha-Sha Ruan, Wen-Zhuo Dai, Rong Li
BACKGROUND: MicroRNA (miR)-125a-3p is reported to play an important role in some central nervous system diseases, such as Alzheimer's disease (AD). However, a study has not been conducted on the mechanism of miR-125a-3p in the pathological process of AD. METHODS: First, we assessed the expression of miR-125a-3p in AD cohort. Subsequently, we altered the expressions of miR-125a-3p to assess its role in cell viability, cell apoptosis, amyloid-β (Aβ) metabolism, and synaptic activity...
September 13, 2023: Current Alzheimer Research
James G McLarnon
INTRODUCTION: The present study has examined microglial and astrocyte activation in association with neuronal degeneration in an animal model using an injection of amyloid-beta peptide Aβ1-42 (Aβ42) plus fibrinogen into rat hippocampus. METHOD: The combination of stimuli is suggested as a novel and potent perturbation to induce gliosis and the production of glial-derived neurotoxic factors in an animal model exhibiting a leaky BBB (blood-brain barrier)...
September 12, 2023: Current Alzheimer Research
Bohong Kan, Zhengjia Dong, Zhenyu Tang, Lan Zhao, Zhen Li
BACKGROUND: Studies have found synaptic plasticity damage to be an early marker of Alzheimer's disease (AD). RhoA/ROCK pathway is involved in the regulation of synaptic plasticity. Acupuncture can significantly improve the cognitive state of AD. OBJECTIVE: We aimed to use modern biological technology to detect the changes in synaptic plasticity and RhoA/ROCK pathway in SAMP8 mice, as well as the intervention effect of acupuncture. METHODS: Morris water maze and electrophysiological techniques were used in vivo to detect the changes in spatial memory and LTP of mice...
September 11, 2023: Current Alzheimer Research
Matthew C Findlay, Majid Khan, Mrinmoy Kundu, Chase M Johansen, Brandon Lucke-Wold
Neurodegenerative diseases (NDDs) encapsulate conditions in which neural cell populations are perpetually degraded and nervous system function destroyed. Generally linked to increased age, the proportion of patients diagnosed with a NDD is growing as human life expectancies rise. Traditional NDD therapies and surgical interventions have been limited. However, recent breakthroughs in understanding disease pathophysiology, improved drug delivery systems, and targeted pharmacologic agents have allowed innovative treatment approaches to treat NDDs...
September 11, 2023: Current Alzheimer Research
Anton J Kociolek, Kayri K Fernandez, Michelle Hernandez, Zhezhen Jin, Stephanie Cosentino, Carolyn W Zhu, Yian Gu, Davangere P Devanand, Yaakov Stern
BACKGROUND AND OBJECTIVES: Neuropsychiatric symptoms (NPS), including psychotic symptoms (hallucinations, illusions, delusions), agitation/aggression, and depressed mood, are common in individuals with Alzheimer's disease (AD) and predict poorer outcomes, including faster disease progression. We aimed to evaluate associations between NPS and cognition and dependence in a multi-ethnic sample of community-dwelling older adults with AD. METHODS: Predictors 3 (P3) is a cohort study of AD disease courses recruiting older adults aged 65 and above residing in upper Manhattan...
September 8, 2023: Current Alzheimer Research
Peng Cheng Han, Eric D Hamlett
Multiple studies have proposed important roles of T cells in the pathogenesis of Alzheimer's disease. Given the successful application of immune-based therapy for cancer and a variety of diseases, T cell-modifying therapy becomes an attractive way to develop new therapies for Alzheimer's disease and perhaps neurodegenerative diseases in general. However, most of these studies address peripheral T cell responses, while direct pathological evidence documenting T cell infiltration relative to Alzheimer's disease pathological markers (i...
September 4, 2023: Current Alzheimer Research
Camilla A Molobekova, Elena M Kondaurova, Tatiana V Ilchibaeva, Alexander Ya Rodnyy, Natalia A Stefanova, Nataliya G Kolosova, Vladimir S Naumenko
AIM: In this study, OXYS rats of three ages (1, 3, and 6 months), a proven model of Alzheimer's disease (AD), at various stages of disease progression were used to thoroughly study the effects of amisulpride on behavior and tau protein phosphorylation. BACKGROUND: With the growing number of patients with AD, the problem of finding a cure is very acute. Neurodegeneration in AD has various causes, one of which is hyperphosphorylation of tau protein. OBJECTIVE: This study aimed to investigate whether amisulpride would affect pathological tau phosphorylation in AD...
August 28, 2023: Current Alzheimer Research
Faruk Kurhan, Mustafa Akın
Alzheimer's disease (AD) ranks first among the causes of dementia worldwide. AD can develop a psychotic manifest at a significant rate. AD prognosis worsens by added psychosis clinic. There is no treatment approved by the United States Food and Drug Administration (FDA) among antipsychotics for Alzheimer's disease Psychosis (ADP). However, pimavanserine, an atypical antipsychotic, has been approved by the FDA for Parkinson's psychosis. It is predicted that pimavanserin, a new antipsychotic, will fill an important gap in this area...
August 25, 2023: Current Alzheimer Research
Can Sheng, Xu Chu, Yan He, Qingqing Ding, Shulei Jia, Qiguang Shi, Ran Sun, Li Song, Wenying Du, Yuan Liang, Nian Chen, Yan Yang, Xiaoni Wang
Growing evidence supports that Alzheimer's disease (AD) could be regarded as a metabolic disease, accompanying central and peripheral metabolic disturbance. Nowadays, exploring novel and potentially alternative hallmarks for AD is needed. Peripheral metabolites based on blood and gut may provide new biochemical insights about disease mechanisms. These metabolites can influence brain energy homeostasis, maintain gut mucosal integrity, and regulate the host immune system, which may further play a key role in modulating the cognitive function and behavior of AD...
August 25, 2023: Current Alzheimer Research
Yaroslav I Molkov, Maria V Zaretskaia, Dmitry V Zaretsky
INTRODUCTION: A major gap in amyloid-centric theories of Alzheimer's disease (AD) is that even though amyloid fibrils per se are not toxic in vitro, the diagnosis of AD clearly correlates with the density of beta-amyloid (Aβ) deposits. Based on our proposed amyloid degradation toxicity hypothesis, we developed a mathematical model explaining this discrepancy. It suggests that cytotoxicity depends on the cellular uptake of soluble Aβ rather than on the presence of amyloid aggregates...
August 21, 2023: Current Alzheimer Research
Binghan Wang, Hui Chen, Jie Shen, Wansi Zhong, Yan Zheng, Min Lou, Lusha Tong, Changzheng Yuan
INTRODUCTION: Sensory impairments (SIs, including visual, hearing, olfactory, and taste impairments) have been individually associated with age-related cognitive function. Little is known regarding their combined associations with cognitive function. METHODS: We included 2,931 participants (mean age of 69.1 years) from the National Health and Nutrition Examination Survey (NHANES, 2011-2014) and 10,785 participants (mean age of 70.2 years) from the National Health Interview Survey (NHIS, 2021)...
August 16, 2023: Current Alzheimer Research
Roxana Noriega-Navarro, Ricardo J Martínez-Tapia, Juan L Osornio-Hernández, Lucia Landa-Navarro, Luis O Xinastle-Castillo, Abraham Landa, Luz Navarro
Thioredoxin1 (Trx1) is a ubiquitous antioxidant protein that regulates the cell's redox status. Trx1's thiol redox activity protects neurons from various physiological processes that cause neuronal damage and neurodegeneration, including oxidative stress, apoptosis, and inflammation. Several studies have found that direct or indirect Trx1 regulation has neuroprotective effects in the brain, protecting against, preventing, or delaying neurodegenerative processes or brain traumas. This review focuses on the term neuroprotection, Trx1 localization, and expression in the brain, as well as its modulation concerning its neuroprotective effect in both animal and clinical models of ischemia, hypoxia, hemorrhage, traumatic brain injury, epilepsy, Alzheimer's disease, and Parkinson's disease...
August 9, 2023: Current Alzheimer Research
Weiming Yuan, Weijia Zhi, Lizhen Ma, Xiangjun Hu, Qian Wang, Yong Zou, Lifeng Wang
BACKGROUND: Alzheimer's disease (AD) is a well-known neurodegenerative disease that gradually induces neural network dysfunction and progressive memory deficits. Neural network activity is represented by rhythmic oscillations that influence local field potentials (LFPs). However, changes in hippocampal neural rhythmic oscillations in the early stage of AD remain largely unexplored. OBJECTIVE: This study investigated neural rhythmic oscillations in 3-month-old APP/PS1 and 5xFAD mice to assess early neural connectivity in AD...
August 8, 2023: Current Alzheimer Research
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.